Navigation Links
Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
Date:8/27/2013

e Light Study to cost more than what is projected; the potential for early termination of Orexigen's North American collaboration agreement with Takeda Pharmaceutical Company Limited; the costs and time required to complete additional clinical, non‐clinical or other requirements prior to any resubmission of the Contrave NDA; the therapeutic and commercial value of Contrave; Orexigen's ability to maintain sufficient capital to fund our operations through potential approval of Contrave in 2014; Orexigen's ability to enter into a collaborative partnership for Contrave outside North America on acceptable terms, if at all; and other risks described in Orexigen's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward‐looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in Orexigen's Annual Report on Form 10‐K filed with the Securities and Exchange Commission March 14, 2013 and its other reports, which are available from the SEC's website (www.sec.gov) and on Orexigen's website (www.orexigen.com) under the heading "Investor Relations." All forward‐looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

 Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. Fate Therapeutics Strengthens Its iPSC Platform
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 ... today the signage of a distribution agreement with ... is now distributing Myriant’s bio-succinic acid in the ... and Ireland, targeting customers in the industrial and ... distribution powerhouse, Azelis offers a far-reaching chemical portfolio ...
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
(Date:9/2/2014)... 2014  Spherix Incorporated (SPEX) -- an intellectual property development company ... today announced that the United States Patent & Trademark ... the month of August that are part of a ... issued patents are: , U.S.RE45,065 issued ... 2014; and , U.S.RE45,095 issued August 26, 2014.  ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is expected ... million in 2014, growing at a CAGR of ... synthesis market is categorized on the basis of ... The synthesized oligonucleotides segment is expected to register ... market during the forecast period, owing to an ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... Mass., Sept. 19 Boston Scientific,Corporation (NYSE: BSX ... Life,Sciences Conference, which is being held September 22 - ... Chief Executive Officer, will make a,30-minute presentation which will ... Thursday, September 25, beginning at approximately 9:00,a.m. ET., ...
... PARK, Ill., Sept. 19 Abbott (NYSE:,ABT) will announce ... before the market opens., The announcement will be ... at 8 a.m. Central time (9 a.m. Eastern), and ... http://www.abbottinvestor.com . An archived edition of the call will ...
... China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... Chinese firm specializing in the manufacture,research, development, ... that at its 2008 Annual General Meeting ... the Company,s nominees to the,Board of Directors., ...
Cached Biology Technology:China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders 2
(Date:9/2/2014)... distribution of media will have lower carbon emissions ... file sizes are large. , That,s the conclusion ... of Industrial Ecology that looked at the ... PlayStation3. Researchers found that Blu-ray Discs delivered via ... game files downloaded over broadband Internet. For their ...
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor core ... in a single season because of injury than are pitchers ... and pelvis. , In the study, 347 pitchers were assessed ... in their pelvis as they raised a leg to step ... at least 30 days cumulative, not consecutive during ...
(Date:9/2/2014)... new study published in the September issue of ... identifies a novel strategy to diagnose the leading ... irreversible structural damage has occurred. This advance involves ... on the endothelium of retinal vessels. Using new ... distinguish the early molecular development of diabetic retinopathy. ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... for hundreds of years as an herbal remedy to prevent ... commonly used herbal medicines in North America. However, in spite ... on the body,s immune system are conflicting. ... University Indianapolis are investigating the possibility that Echinacea has other ...
... 20 million people in the U.S., and many more worldwide, ... developing mesothelioma, a malignant cancer of the membranes that cover ... Moreover, asbestos exposure increases the risk of lung cancer among ... understand why asbestos causes cancer. The answer ...
... Tuesday 29 June 2010, announces this year,s award winners ... to theoretical physicist Professor Edward Witten for outstanding, transformative ... influential physicists of the past 30 years, he has ... particle physics and cosmology to theoretical areas of string ...
Cached Biology News:Mystery unraveled: How asbestos causes cancer 2IOP announces 2010 award winners 2